Funding
← Back to your selection

Invus

Activity from announced rounds

Activity in this selectionSeries B

Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.

Recorded funding activity

Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.

Sources
Rounds participated in
4
Confirmed lead rounds
0
3 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$577M
4 disclosed · full round size, not this investor’s share

By stage

Series B4

By primary sector

Biotech4

By country

United States4

Rounds

4 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
City Therapeutics

City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.

$99.5MSeries B
Role not disclosed
Contraline

Develops hormonal and non-hormonal male contraceptives for men and couples globally

$92.5MSeries B
Role not disclosed
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B
Role not disclosed